Full Text View
Tabular View
No Study Results Posted
Related Studies
Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors
This study is ongoing, but not recruiting participants.
Study NCT00594633   Information provided by Memorial Sloan-Kettering Cancer Center

First Received on January 7, 2008.   Last Updated on January 7, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Brain Tumor
Brain Cancer
Cns Cancer
Cognitive Dysfunction
Additional conditions recognized in this trial
Brain Neoplasms
Central Nervous System Neoplasms
Cognition Disorders
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Neoplasms
Neoplasms by Site
Nervous System Diseases
Nervous System Neoplasms
Interventions listed in this trial
donepezil and questionaires
Additional drug interventions recognized in this trial
Donepezil
More general drug interventions related to this trial
Central Nervous System Agents
Cholinergic Agents
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nootropic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Memorial Sloan-Kettering Cancer Center
Weill Medical College of Cornell University


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services